H.C. Wainwright lowered the firm’s price target on Clearside Biomedical (CLSD) to $5 from $6 and keeps a Buy rating on the shares following the Q1 report. The firm’s estimated market value of the company remains unchanged, but the projected shares outstanding have increased.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Clearside Biomedical Reports Q1 2025 Financial Progress
- Clearside Biomedical: Undervalued Opportunity with Strategic Partnerships and Promising CLS-AX Advancements
- Clearside Biomedical reports Q1 EPS (11c), consensus (11c)
- Clearside Biomedical announces six presentations related to CLS-AX
- Buy Rating for Clearside Biomedical Backed by Promising Trial Results and FDA Alignment